Search is not available for this dataset
Therapeutic
stringlengths 8
15
| Format
stringlengths 3
52
| CH1 Isotype
stringclasses 15
values | VD LC
stringclasses 9
values | Highest_Clin_Trial (Oct '21)
stringclasses 12
values | Est. Status
stringclasses 4
values | Heavy Sequence
stringlengths 2
132
| Light Sequence
stringlengths 2
113
| Heavy Sequence (if bispec)
stringlengths 2
132
| Light Sequence (if bispec)
stringlengths 2
112
| 100% SI Structure
stringlengths 7
224
⌀ | 99% SI Structure
stringlengths 7
364
⌀ | 95-98% SI Structure
stringlengths 7
207
⌀ | Year Proposed
int64 1.99k
2.02k
| Year Recommended
stringclasses 30
values | Target
stringlengths 2
75
| Companies
stringlengths 2
1.7k
| Conditions Approved
stringlengths 2
277
| Conditions Active
stringlengths 2
910
| Conditions Discontinued
stringlengths 2
384
⌀ | Development Tech
stringlengths 2
149
| Notes
stringlengths 8
194
⌀ | Heavy Sequence second
stringlengths 127
158
⌀ | Light Sequence second
stringlengths 116
136
⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Relatlimab | Whole mAb | G4 | Kappa | Phase-II/III | Active | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK | na | na | null | null | null | 2,018 | 2019 | LAG3 | Bristol-Myers Squibb;Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | na | Malignant melanoma;Colorectal cancer;Gastric cancer;Renal cell carcinoma;Solid tumours;Oesophageal cancer;Glioblastoma | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Hodgkin's disease;Mantle-cell lymphoma;Non-Hodgkin's lymphoma | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFSDY YWNWIR QPPGKGL EWIGEINH RGSTNSNPSLK SRVTLSLD TSKN QFSLKLRSVT AADT AVYYCAF GYSDYEY NWF DPWGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS ISSYLAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWPL T FGQGT NLEI K |
Relfovetmab | Feline Whole mAb | G1 | Kappa | Unknown | Active | DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYWMHWVRQAPGKGLQWVARIDPYGGGTKHNEKFKRRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRSGYDYYFDVWGQGTLVTVSS | EIQMTQSPSSLSASPGDRVTITCRASENIYSFLAWYQQKPGKVPKLLIYNANTLAEGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQHHFGTPFTFGSGTKLEIK | na | na | null | null | null | 2,018 | 2019 | NGFB | na | na | na | na | na | null | D VQLVE SGGD LV KPGG SLRLTCVA SGF TY SN YWMHWVRQ APGKG LQWVARI DPYGGGTKHNEK FKRRFTISR DNAKN TLYLQMN SLKTEDTA TYYCVR SGYD YYFDVW GQG TLVTVS S | EI QMT QSPSSLSASPGD RVTITCR ASEN IYSFLAWYQ QKPGKVP KLLIYN ANTLAEGVPSRFSGSGSGTD FTLTIS SLE PEDAATYYCQH HFGTPF T FGSGT KLEI K |
Remtolumab | Bispecific Dual Variable Domain IG | G1;G1 | Kappa;Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK | EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS | EIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIK | 4nyl:EF:AB:HL:CD/6cr1:HL;None | 3wd5:HL;None | None;None | 2,016 | 2017 | IL17A;TNFA | Abbott Laboratories;Abbvie | na | na | Psoriatic arthritis;Rheumatoid arthritis | Dual Variable Domain Immunoglobulin Technology | null | E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVRQ APGKGL EWVSAITW NSGH ID YADSVE GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAKVSYL STASSLD Y WGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG IRNYLAWYQ QKPGKAP KLLIYAA STLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQR YNRAPY T FGQGT KVEI K |
Reozalimab | Bispecific mAb | G1;G1 | Kappa;Lambda | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPSFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARSPDYSPYYYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVNWYQQLPGTAPKLLIYGNSNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCQSYDSSLSGSVFGGGIKLTVL | None;None | None;None | None;None | 2,022 | na | PDCD1;CD274 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGLII PSFDTAGY A Q K FQG RVAITV DESTS TAYMELS SLRSEDT AVYYCARAE HSSTG TFDY WGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K |
Reslizumab | Whole mAb | G4 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAVSGLSLTSNSVNWIRQAPGKGLEWVGLIWSNGDTDYNSAIKSRFTISRDTSKSTVYLQMNSLRAEDTAVYYCAREYYGYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCLASEGISSYLAWYQQKPGKAPKLLIYGANSLQTGVPSRFSGSGSATDYTLTISSLQPEDFATYYCQQSYKFPNTFGQGTKVEVK | na | na | null | null | null | 2,001 | 2002 | IL5 | Celltech R&D;Schering-Plough;Allergy and Asthma Clinical Research;Celltech R&D;Teva Pharmaceutical Industries | Asthma | Sinusitis;Churg-Strauss syndrome | Oesophagitis | na | null | E VQLVES GGG LV QPGG SLRLSCAV SGL SL TSNS VNWIR QAPGKGL EWVGLIWS NGDTDYNSA IKSRFTIS RDTSKS TVYLQM N S LRAEDT AVYYCARE YYG YFD YWGQG TLVTV SS | DIQMTQSPSS LSA SVGD RVTITCL ASEG ISSYLAWYQ QKPGKAP KLLIYG ANSLQTGVPSRFSGSGSATD YTLTIS SLQ PEDFAT YYCQ QSYKFPNTFGQGT KVEV K |
Resugobart | Whole mAb | G4 | Kappa | TBC | Active | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNLDWLRQAPGEGLEWIGDIDPNDGDILYNQKFRDRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRWAYYFDYWGQGTTVTVSS | DIVMTQSPSSLSASVGDRVTITCKASQSVSNDVAWYQQKPGKSPKLLIYYTSNRFTGVPDRFSGSGSGTDFTLTISSLQPEDFATYFCQQDYSSPVTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | SOST | TBC | TBC | TBC | TBC | TBC | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTD YN LDWLR QAPGEGL EWIG DIDPNDGD ILY NQKFRD RVTMTT DTSTS TAYMELRS LRSDDT AVYYCA R RWAYYFD YWGQG TTVTVS S | D IVMT QSPSS LSA SVGD RVTITCK ASQSVSND VAWYQ QKPGKSP KLLIYYT SNRFTGVPDRFSGSGSGTD FTLTISS LQP EDFAT YFC QQDYSSP VTF GGG TKVEI K |
Retifanlimab | Whole mAb | G4 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYWMNWVRQAPGQGLEWIGVIHPSDSETWLDQKFKDRVTITVDKSTSTAYMELSSLRSEDTAVYYCAREHYGTSPFAYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASESVDNYGMSFMNWFQQKPGQPPKLLIHAASNQGSGVPSRFSGSGSGTDFTLTISSLEPEDFAVYFCQQSKEVPYTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | PDCD1 | MacroGenics;Incyte Corporation;ZAI Lab | na | Gastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma | Haematological malignancies | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYS FTSYWMNWVR QAPGQGL EWIGVI HPSDSET WL DQKFKD RVTITVD KSTS TAYMELS SLRSEDT AVYYCAR EHYGTSPF AYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCRA SESVDNYGM SFMN W F QQKPGQPP KLLIHA ASNQGSGVPS R FSGSGSGTD FTLTIS SLEPED FAVYFC QQSKEVP YT FGGG TKVEI K |
Retlirafusp | Whole mAb Fusion | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS | DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK | na | na | null | null | null | 2,020 | 2021 | CD274 | Jiangsu Hengrui Medicine | na | Pancreatic cancer;Solid tumours;Head and neck squamous cell carcinoma | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGRI GPNSGFTSYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RGGSSYD YFD YWGQG TTVTVS S | D IVLTQ SPA SLAV SPGQ RATITCR ASE SVSIH G THLMHWYQ QKPGQPP KLLIYAA SNLESGVP ARFS GSGSGT DFTLTIN PVEAEDTA NYYCQQ SFEDPL T FGQGT KLEI K |
Revdofilimab | Whole mAb | G1 | Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYGMSWVRQAPGKGLELVATINSNGGRTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGITTAYAMDYWGQGTTVTVSS | DIVMTQSPDSLAVSLGERATINCKASQSVDYDGDSYMHWYQQKPGQPPKLLIYAASILESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQSNEDPRTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | TNFRSF4 | AbbVie | na | Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSR YG MSWVRQ APGKG LELVATIN SNGG RTY YPDSVKG RFTISR DNAKNS LYLQMN SLRAED TAVYYCA REGI TTAYAMD YWGQG TTVTVS S | D IVMT QSPDS LAVS LGER ATINCK ASQ SV DYDGD SYMHWYQ QKPGQPP KLLIYAASIL ESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQ QSNEDPRTFGGG TKVEI K |
Rilotumumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | QVQLQESGPGLVKPSETLSLTCTVSGGSISIYYWSWIRQPPGKGLEWIGYVYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLNSVTAADTAVYYCARGGYDFWSGYFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASQSVDSNLAWYRQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYINWPPITFGQGTRLEIK | na | na | null | null | null | 2,009 | 2010 | HGF | Amgen;Astellas Pharma | na | na | Colorectal cancer;Gastric cancer;Glioma;Prostate cancer;Renal cancer;Small cell lung cancer;Solid tumours | Abgenix XenoMouse | null | QV QLQE SGPGL V KPSE TLSLTCTV SGGS ISIYYWSWIR QPPGKGL EWIGYVYYS GSTNYNPSLK SRVTISVD TSKN QFSLKL N S VTAADT AVYYCA RGGYDF W SG YF DYWGQG TLVTVS S | E IVMT QSPA TLSV SPGE RATLSCRA SQSVDSN LAWYR QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQYI NWPPI T FGQGT RLEI K |
Riltovetbart | Whole mAb | G2 | Kappa | TBC | Active | EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS | EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | IL31 (Canine) | TBC | TBC | TBC | TBC | TBC | null | E VQLVE SGGD LV KPGG SLRLSCVA SGF TF SNYG MSWVRQ APGKG LQWVATIS YGGS YTY YPDNIK GRFTISR DNAKN TLYLQMN SLRAEDT AMYYCVR GYGYDTMDYWGQG TLVTVS S | E IVMT QSPA SLS LSQEE KVTITCK ASQ SVSF AGTG LMHWYQ QKPGQAP KLLIYRA SNLEAGVPSRFSGSGSGTD FSFTIS SLEPED VAVYYCQ QSREYPW T FGQGT KLEI K |
Rilvegostomig | Bispecific mAb | G1;G1 | Kappa;Lambda | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYGMHWVRQAPGKGLEWVAYISSGSYTIYSADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARRAPNSFYEYYFDYWGQGTTVTVSS | QIVLTQSPATLSLSPGERATLSCSASSKHTNLYWSRHMYWYQQKPGQAPRLLIYLTSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQWSSNPFTFGQGTKLEIK | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYAGEVKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPLPLHYYGMDVWGQGTTVTVSS | QSVLTQPPSASGTPGQRVTISCSGSSSNIGRRPVNWYQQLPGTAPKLLIYSQNQRPSGVPDRFSGSQSGTSASLAISGLQSEDEADYFCAVWDDIGRVLQLGGGTQLTVL | None;None | None;None | None;None | 2,022 | na | PDCD1;TIGIT | TBC | TBC | TBC | TBC | TBC | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SDYG MHWVRQ APGKG LEWVAYIS SGS YTIYS ADSVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCAR RAPNSF YEYYFD YWGQG TTVTVS S | Q IVLTQ SPA TLSL SPGE RATLSCS ASSKHTN LYWSRHMYWYQ QKPGQAP RLLIYLT SNRATGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCQQ WSSNPF TF GQGT KLEI K |
Rimteravimab | Mixed Nanobody (VHH-CH2-CH3 dimer) | G1 | na | Phase-I/II | Active | DVQLVESGGGLVQPGGSLRLSCAASGRTFSEYAMGWFRQAPGKEREFVATISWSGGATYYTDSVKGRFTISRDNAKNTVYLQMNSLRPEDTAVYYCAAAGLGTVVSEWDYDYDYWGQGTLVTVSS | na | na | na | null | null | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | ExeVir | na | COVID-19 | na | na | Also complementary vs. SARS-CoV Spike RBD and WIV-CoV Spike RBD | D VQLVES GGG LV QPGG SLRLSC AASGRT FSEYAMGWFR QAPGKER EFVATISW SGGA TYYT DSVKG RFTISR DNAKN TVYLQMN SLRPEDT AVYYCA AAGLG TVVSEWD YDYDYWGQG TLVTVS S | null |
Rinucumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QLQLQESGPGLVKPSETLSLTCTVSGGSITSSSYYWGWIRQPPGKGLEWIGSIYYRGSTNYNPSLKSRVTISVDSSKNQFYLKVSSVTAVDTAVYYCARQNGAARPSWFDPWGQGTLVTVSS | EIVLTQSPDTISLSPGERATLSCRASQSISSIYLAWYQQKPGQAPRLLIYGASSRVTGIPDRFSVSGSGTDFTLTISRLEPEDFAVYYCQHYGISPFTFGPGTKVDIR | na | na | null | null | null | 2,015 | 2016 | PDGFRB | Regeneron Pharmaceuticals | na | na | Wet age-related macular degeneration | na | null | QL QLQE SGPGL V KPSE TLSLTCTV SGGS IT SSS YYWGWIR QPPGKGL EWIGSIYYR GSTNYNPSLK SRVTISVD SSKN QFYLKVSS V T AVDT AVYYCA RQNGAARPS WF DPWGQG TLVTV SS | E IVLTQ SPD TISL SPGE RATLSCR ASQSI S SIYLAWY QQKPGQAP RLLIYG ASSRVTGIPD RFSVS GSGT DFTLTISR LE PEDFAVYYCQHY GISPF T FGPGT KVD IR |
Ripertamab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK | na | na | 2osl:HL:AB/6y90:HL:CD/6vja:HL:IM | 4kaq:HL | null | 2,019 | 2020 | MS4A1 | Sinocelltech | na | Non-Hodgkin's lymphoma | na | na | Chimeric, Likely to be a Rituximab biosimilar | QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K |
Risankizumab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK | na | na | null | null | null | 2,015 | 2016 | IL23A | AbbVie;Boehringer Ingelheim | Erythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis | Crohn's disease;Ulcerative colitis;Atopic dermatitis | Psoriasis;Ankylosing spondylitis;Asthma | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TF TDQ TIHWMR QAPGQGL EWIGYIY PRDDSPKYNENFKG KVTITA DKSTS TAYMELSS LRSEDT AVYYCAI PDRSGY AWFIYW GQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASRD VAIAVAWY QQKPGKVP KLLIYWA STRHTGVPSRFSGSGSRTD FTLTIS SLQ PEDVADYFCHQ YSSYPF TF GSGT KLEI K |
Rituximab | Whole mAb | G1 | Kappa | Approved | Active | QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK | na | na | 2osl:HL:AB/6y90:HL:CD/6vja:HL:IM | 4kaq:HL | null | 1,997 | 1998 | MS4A1 | Biogen;Biogen Idec;Cedars-Sinai Medical Center;Chugai Pharmaceutical;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Janssen Research & Development;M. D. Anderson Cancer Center;Mayo Clinic;Nagoya University;Oregon Health & Science University;Roche;SCRI Development Innovations;Takeda Oncology;University of Gottingen;University of Texas M. D. Anderson Cancer Center;University of Tours;Zenyaku Kogyo | Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Follicular lymphoma;Idiopathic thrombocytopenic purpura;Lymphoproliferative disorders;Microscopic polyangiitis;Nephrotic syndrome;Non-Hodgkin's lymphoma;Pemphigus vulgaris;Rheumatoid arthritis;Wegener's granulomatosis | Mantle-cell lymphoma;Transplant rejection;Neuromyelitis optica;B-cell lymphoma;Chronic inflammatory demyelinating polyradiculoneuropathy;Glomerulonephritis;Precursor cell lymphoblastic leukaemia-lymphoma;Renal transplant rejection | Multiple sclerosis;Ocular inflammation;Primary biliary cirrhosis;Scleritis;Sjogren's syndrome;Ulcerative colitis;Dermatomyositis;Graft-versus-host disease;Lupus nephritis;Systemic lupus erythematosus | na | null | QV QLQ QPGA ELV KPGA SVKMSCK ASGY TFTSYNMHWVK QTPGRG LEWIGAI YPGNGDTSYNQK F KG KATLTA DKSSST AYMQLS SLTSEDS AVYYCAR S T YYGGD WYFNVW GAGT TVTVS A | Q IVLS QSP AILS ASPGE KVTMTCR ASSS VSYIHWFQ QKPGSSPKP WIYAT SNLASGV PVRFS GSGSGT SYSLTISRVE AEDA ATYYCQQW TSNPPTFGGGT KLEI K |
Rivabazumab | Fab | G1 | Kappa | Phase-II | Discontinued | EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYPMHWVRQAPGKGLEWVAVISYDGSEKWYADSVKGRFTISRDNSKNTLYLEMNSLRPEDTAVYYCARNRGDIYYDFTYAMDIWGQGTTVTVSS | DIQLTQSPSTLSASVGDSVTITCRASEGVDRWLAWYQQKPGRAPKLLIYDASTLQSGVPSRFSGSGSGTEFSLTISSLQPDDVATYYCQHFWGTPYTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | PcrV type III secretion system | KaloBios Pharmaceuticals Inc | na | na | Infectiology;Inflammation;Inherited diseases | Humaneering Technology | null | E VQLVES GGG VV QPGR SLRLSC AASGF TF SNYP MHWVRQ APGKG LEWVAVISY DGSE KWYAD SVKG RFTISR DNSKN TLYLEMN SLRPEDT AVYYCA RNRGD IYYDFTYAMDI WGQG TTVTVS S | DI QLT QSPS TLSAS VGD SVTITCR ASEGVD R WLAWYQ QKPGRAP KLLIYD ASTLQSGVPS R FSGSGSGT EFSLTIS SLQPDDV ATYYCQH FWGTPY T FGQGT KLEI K |
Robatumumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSFAMHWVRQAPGKGLEWISVIDTRGATYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLGNFYYGMDVWGQGTTVTVSS | EIVLTQSPGTLSVSPGERATLSCRASQSIGSSLHWYQQKPGQAPRLLIKYASQSLSGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQSSRLPHTFGQGTKVEIK | na | na | null | null | null | 2,008 | 2009 | IGF1R | Merck & Co;Schering-Plough | na | na | Colorectal cancer;Osteosarcoma;Sarcoma;Solid tumours | na | null | E VQLVQS GGG LV KPGG SLRLSC AASGF TFSSFAMHWVR QAPGKGL EWISVID TRGA TYYAD SVKG RFTIS RDNAKN SLYLQMNS LRAEDT AVYYCAR LGN FYYGMDV WGQG TTVTVS S | E IVLTQ SPG TLSV SPGER ATLSCR ASQSIGS SLHWYQ QKPGQAP RLLIKYA SQSLSGIPDRFSGSGSGTD FTLTISR LEPED FAVYYCH QSSRLPHTFGQG TKVEI K |
Rocatinlimab | Whole mAb | G1 | Kappa | Phase-III | Active | QITLKESGPTLVKPKQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAVIYWDDHQLYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCAHRRGAFQHWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDSSLTFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | TNFRSF4 | Kyowa Hakko Kirin | na | Ulcerative colitis;Atopic dermatitis | na | na | null | Q ITLK ESGP TLV KPKQ TLTLTCTF SG FSLS TSGM GVGWIR QPPGKA LEWLAVIYW DDHQ L YSPSLK SRLTITK DTSKN QVVLTMT NMDPVDT ATYYCA HRRGA FQH WGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYDSS LTF GGG TKVEI K |
Roledumab | Whole mAb | G1 | Kappa | Phase-II/III | Active | QVQLVESGGGVVQPGRSLRLSCTASGFTFKNYAMHWVRQAPAKGLEWVATISYDGRNIQYADSVKGRFTFSRDNSQDTLYLQLNSLRPEDTAVYYCARPVRSRWLQLGLEDAFHIWGQGTMVTVSS | AIRMTQSPSSFSASTGDRVTITCRASQDIRNYVAWYQQKSGKAPKFLIYAASTLQSGVPSRFSGSGSGTDFTLTINSLQSEDFATYYCQQYYNSPPTFGQGTRVEIT | na | na | null | null | null | 2,010 | 2011 | RHD | LFB Biotechnologies | na | Haemolytic disease of newborn | na | EMABling Platform | null | Q VQLVES GGG VV QPGR SLRLSCT ASGF TFKNYAMHWVRQ APAKGL EWVATISY DGR NIQYA DSVKG RFTFS RDNSQD TLYLQLN SLRPEDT AVYYCA RPVRS RWLQL GLEDA FHIW GQG TMVTVS S | AI RMT QSPSS FS ASTGD RVTITCR AS QDIRNYVAWYQQK SGKAP KFLIYAA STLQSGVPSRFSGSGSGTD FTLTIN SLQSED FATY YC QQY YNSPPTFGQGT RVEI T |
Rolinsatamab | Whole mAb ADC | G1 | Kappa | Phase-I | Active | EVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWIGEIDPSDSYSNYNQKFKDRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNGGLGPAWFSYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCKASQYVGTAVAWYQQKPGKSPKLLIYSASNRYTGVPSRFSDSGSGTDFTLTISSLQPEDFATYFCQQYSSYPWTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | PRLR | AbbVie | na | Solid tumours | na | na | null | E VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTTYWMHWVR QAPGQG LEWIGEI DPSDSYSNYNQKFKD RATLTVD KSTS TAYMELS SLRSEDT AVYYCA RNGGLGP AWFSY WGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCK ASQY VGTAVAWYQ QKPGKSP KLLIYS ASNRYTGVPSRFSDSGSGTD FTLTIS SLQ PEDFATYFCQQ YSSYPW T FGGG TKVEI K |
Romilkimab | Bispecific Dual Variable Domain IG | G1;G1 | Kappa;Kappa | Phase-II | Discontinued | EVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSS | DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIK | QVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSS | DIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIK | None;None | None;None | None;None | 2,017 | 2018 | IL13;IL4 | Sanofi | na | na | Idiopathic pulmonary fibrosis;Systemic scleroderma | na | null | E VQLKE SGPG LV APGG SLSITCTV SG FS LTDS SINWVR QPPGKGL EWLGMIW GDGR I D YADALKSR LSI SKDSSKS QVFLEMTS LRTDDT ATYYCA RDGYFPY AMD FWGQGT SVTVS S | D IVLT QSPA SLAVS LGQ RATISCR ASESVDSYGQ SYMHWYQQK AGQPP KLLIYLA SNLESGVPA RF SGSGSRTD FTLTI DPVQ AEDAATYYCQQ NAEDSRTFGGGT KLEI K |
Romlusevimab | Whole mAb | G1 | Lambda | Phase-II/III | Active | QVQLVQSGSELKKPGASVKVSCKASGYTFTTYVMNWVRQAPGQGLEWMGWINTNTGNPTYAQGFTGRFVFSLDTSVSTASLQISSLKAEDTAVYYCSSEITTLGGMDVWGQGTTVTVSS | SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISGVEAGDEADYYCQVWDSISDHRVFGGGTKLTVL | na | na | null | null | null | 2,021 | 2022 | SARS-CoV-2 Spike RBD | Brii Biosciences | na | COVID-19 | na | na | null | Q VQLVQ SGS E LKKPGA SVKVSCK ASGY TFTTYVMNWVR QAPGQGL EWMGWIN TNTGNPTYAQG FTGRFVFSL DTSVS TASLQISS LKAEDT AVYYCS SE ITT LGG MDV WGQG TTVTVS S | SY VL TQPPS VSV APGK TARITC GGNNIGSK SVHWYQ QKPGQAP VLVIYY DSDRPSGIPERFSGSNSGN TATLTISGV EAGDE ADYYCQVWD SISDH RVF GGGT KLTV L |
Romosozumab | Whole mAb | G2 | Kappa | Approved | NFD | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMHWVRQAPGQGLEWMGEINPNSGGAGYNQKFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARLGYDDIYDDWYFDVWGQGTTVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGDTLPYTFGGGTKVEIK | na | na | null | null | null | 2,011 | 2012 | SOST | ChiroscienceGroup plc;Amgen;UCB | Male osteoporosis;Postmenopausal osteoporosis | na | Fracture | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT DYN MHWVRQ APGQG LEWMGEI NPNSGGAGYNQ KFKGRVTMTT DTSTS TAYMELRS LRSDDT AVYYCAR LGYDDIYDD WYFDV WGQG TTVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGKAP KLLIYYT SRLLSGVPS R FSGSGSGTD FTLTIS SLQPE DF ATYYC QQGDTLP YTF GGGT KVEI K |
Rontalizumab | Whole mAb | G2 | Kappa | Phase-II | Discontinued | EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYIIHWVRQAPGKGLEWVASINPDYDITNYNQRFKGRFTISLDKSKRTAYLQMNSLRAEDTAVYYCASWISDFFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSVSTSSYSYMHWYQQKPGKAPKVLISYASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQHSWGIPRTFGQGTKVEIK | na | na | 4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY | null | null | 2,009 | 2010 | IFNA1 | Chugai Pharmaceutical;Genentech | na | na | Systemic lupus erythematosus | na | null | E VQLVES GGG LV QPGG SLRLSC ATSGY TFTEYIIHWVR QAPGKG LEWVASI NPDYDITNYNQRFK GRFTISL DKSKR TAYLQMN SLRAEDT AVYYCA SWISDFF DYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQSVSTSSY SYMHWYQ QKPGKAP KVLISYA SNLESGVPS R FSGSGSGTD FTLTISS LQPED F ATYYCQ HSWGIPRTFGQGT KVEI K |
Rosmantuzumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSIHWVRQAPGQGLEWIGYIYPSNGDSGYNQKFKNRVTMTRDTSTSTAYMELSRLRSEDTAVYYCATYFANNFDYWGQGTTLTVSS | DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISPVQAEDFATYYCQQSNEDPLTFGAGTKLELK | na | na | null | null | null | 2,016 | 2017 | RSPO3 | OncoMed Pharmaceuticals | na | na | Colorectal cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF T DYSIHWVRQ APGQG LEWIGYIY PSNGDSGYNQKFKN RVTMTR DTSTS TAYMELSR LRSEDT AVYYCATYF ANNFDYWGQG TTLTVS S | DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA SNLESGVPSRFSGSGSGTD FTLTIS PVQ AEDFA TYYCQ QSNEDPL TF GAGT KLEL K |
Rosnilimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVQSGSELKKPGASVKVSCKASNYTFTDYSMHWVRQAPGQGLEWMGWINIETYYPTYADQFKGRFAFSLDTSVSTAYLQISSLKAEDTAVYYCARDYYGRFYYAMDYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCTASSSVSSSYFHWYQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPLTFGGGTKVEIK | na | na | null | null | null | 2,022 | na | PDCD1 | AnaptysBio | na | Alopecia areata;Autoimmune disorders | na | na | null | Q VQLVQ SGS E LKKPGA SVKVSCK ASNY TFT DY SMHWVRQ APGQGL EWMGWINIET YYPTYADQFKG RFAFSL DTSVS TAYLQISS LKAEDT AVYYCAR DYYGR FYYAMD YWGQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCTA SSSVSSS YFHWYQ QKPGQAP RLLIYS TSNLASGIP ARFS GSGSGT DFTLTISR LEPED FAVYYCH QYHRSPL TF GGG TKVEI K |
Rosopatamab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYNQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS | DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSRFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK | na | na | null | null | null | 2,019 | 2020 | FOLH1 | Weill Cornell Medical | na | Prostate cancer;Cancers | na | na | null | E VQLVQ SGPEVKKPGA TVKISC KTSGY TFTEYTIHWVK QAPGKG LEWIGNI NPNNGGTT Y NQKFEDK ATLTVD KSTDT AYMELSS LRSEDT AVYYCA AGW NF DYWGQG TLLTVS S | DI QMT QSPSS LS TSVGD RVTLTCK ASQDVGT AVD WY QQKPGPSP KLLIYWA STRHTGIPSRFSGSGSGTD FTLTIS SLQ PEDFADYYCQQ YNSYPL TF GPGT KVDI K |
Rovalpituzumab | Whole mAb ADC | G1 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGEPTYADDFKGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARIGDSSPSDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCKASQSVSNDVVWYQQKPGQAPRLLIYYASNRYTGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQDYTSPWTFGQGTKLEIK | na | na | null | null | null | 2,015 | 2016 | DLL3 | Bristol-Myers Squibb;Stemcentrx | na | na | Small cell lung cancer;Solid tumours | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVR QAPGQGL EWMGWIN TYTGEPT Y ADDFKG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCARI GDSSPSDYWGQ GTLVTVS S | E IVMT QSPA TLSV SPGE RATLSCK ASQSVSND VVWYQ QKPGQAP RLLIYYA SNRYTG I P ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QDYTSPW T FGQGT KLEI K |
Rovelizumab | Whole mAb | G4 | Kappa | Phase-III | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNNWMQWVRQAPGQGLEWMGAIFPGDDETRYTQKFRGKATITADTSTSTAYMELSSLRSEDTAVYYCGRGGKLRPFALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASESVESYGNNFMYWYQQKPGKAPKLLIYLASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCHQDNEDPPTFGQGTKLEIK | na | na | null | null | null | 1,999 | 2000 | CD11 | ICOS Corporation | na | na | Adult respiratory distress syndrome;Cerebral vasospasm;CNS trauma;Multiple sclerosis;Myocardial infarction;Peripheral arterial occlusive disorders;Shock;Stroke;Vascular restenosis | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TNN WMQWVR QAPGQGL EWMGAI FPGDDET RYTQKF RG KATITA DTSTS TAYMELS SLRSEDT AVYYC GRGGK L R PFALD YWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASESV ES YGNN FMYWYQ QKPGKAP KLLIYLA SNLESGVPS RF SGSGSGTD FTLTIS SLQPEDF ATYYCH QDNEDPPTFGQGT KLEI K |
Rozanolixizumab | Whole mAb | G4 | Kappa | Phase-III | Active | EVPLVESGGGLVQPGGSLRLSCAVSGFTFSNYGMVWVRQAPGKGLEWVAYIDSDGDNTYYRDSVKGRFTISRDNAKSSLYLQMNSLRAEDTAVYYCTTGIVRPFLYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKSSQSLVGASGKTYLYWLFQKPGKAPKRLIYLVSTLDSGIPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQGTHFPHTFGQGTKLEIK | na | na | 6fgb:HL | null | null | 2,016 | 2017 | FCGRT | UCB | na | Chronic inflammatory demyelinating polyradiculoneuropathy;Idiopathic thrombocytopenic purpura;Myasthenia gravis | Immunological disorders | na | null | EVP LVE SGGG LV QPGG SLRLSCAV SGF TF SNY GMVWVRQ APGKG LEWVAYI DSDGDN TYYRD SVKG RFTIS RDNAKS SLYLQMN SLRAEDT AVYYC TTGI V R PFLYW GQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITC KSSQ SLV GASGK TYLYWLFQ KPGKAPK RLIYLVST LDSGIPS RF SGSGSGT EFTLTISS LQPEDF ATYYCL QGTHFPHTFGQGT KLEI K |
Rozibafusp | Whole mAb Fusion | G2 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMSWVRQAPGKGLEWVAYIKQDGNEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGILWFGDLPTFWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQGISNWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYDSYPRTFGQGTKVEIK | na | na | 6x4t:BE:DF | null | null | 2,018 | 2019 | ICOS | Amgen | na | Systemic lupus erythematosus | Rheumatoid arthritis | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYWMSWVR QAPGKG LEWVAYIK QDGN EKYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA REG ILWF GDLPTFWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQG ISNWLAWYQ QKPEKAPK SLIYAA SSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFAT YYCQ QYDSYPRTFGQGT KVEI K |
Rulonilimab | Whole mAb | G1 | Kappa | Phase-II/III | Active | EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSWVRQTPEKRLEWVATISGGGRDTYYPDSVKGRFTISRDNAKNNLYLQMSSLRSEDTALYYCARQKDTSWFVHWGQGTLVTVSS | EIVLTQSPATLAVSPGERATISCRASESVDDYGISFMNWFQQKPGQPPKLLIYVASNQGSGVPARFSGSGSGTDFTLNIHPMEEDDTAMYFCQQSKEVPWTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | PDCD1 | Shandong New Time Pharmaceutical | na | Liver cancer | Lymphoma;Solid tumours | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFSS YG MSWVR QTPEKR LEWVATIS GGGRDTYYPDSVK GRFTISR DNAKNN LYLQMSS LRSEDT ALYYCAR QKDTS WFVHW GQG TLVTVS S | E IVLT QSPA TLAV SPGE RATISCRA SESVDDY GISFMNWF QQKPGQPP KLLIYVA SNQGSGVP ARFS GSGSGTD FTLNIH PMEEDDT AMYFCQ QSKEVPW T FGGGT KLEI K |
Runimotamab | Bispecific mAb | G1;G1 | Kappa;Kappa | Phase-I | Active | EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | EVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQGLEWIGWIYPGDGNTKYNEKFKGRATLTADTSTSTAYLELSSLRSEDTAVYYCARDSYSNYYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK | 1fvc:DC:BA/4hkz:BA/1n8z:BA/4ub0:HL/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC;None | 1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC;None | 5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL;None | 2,020 | 2021 | ERBB2;CD3E | Genentech | na | Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K |
Ruplizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS | DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK | na | na | 1i9r:HL:KM:XY/6w4w:HL | null | null | 2,000 | 2001 | CD40LG | Biogen | na | na | Autoimmune disorders;Haemophilia A;Idiopathic thrombocytopenic purpura;Multiple sclerosis;Renal transplant rejection;Systemic lupus erythematosus | na | null | Q VQLVQ SGA EVV KPGA SVKLSCK ASG YIFTSYYMYWVKQ APGQG LEWIGEI NPSNGDTNFNEKFKS KATLTV DKSAS TAYMELSS LRSEDT AVYYCTR SDGRNDMDSWGQ GTLVTVS S | D IVLTQ SPA TLSV SPGE RATISCRA SQRVSSST YSYMHWYQ QKPGQPP KLLIKYA SNLESGVP ARFS GSGSGTD FTLTISS VEPEDF ATYYCQ H SWE IPPTFGGG TKLEI K |
Sabatolimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGDIYPGNGDTSYNQKFKGRVTITADKSTSTVYMELSSLRSEDTAVYYCARVGGAFPMDYWGQGTTVTVSS | AIQLTQSPSSLSASVGDRVTITCRASESVEYYGTSLMQWYQQKPGKAPKLLIYAASNVESGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCQQSRKDPSTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | HAVCR2 | Novartis | na | Chronic myelomonocytic leukaemia;Myelodysplastic syndromes;Acute myeloid leukaemia;Myelofibrosis;Solid tumours;Glioblastoma | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY TFTSYNMHWVRQ APGQG LEWMGDI YPGNGDTSYNQK F K GRVTITA DKSTS TVYMELS SLRSEDT AVYYCARV GGAFPMDYWGQG TTVTVS S | AI QLT QSPSS LSA SVGD RVTITCR ASES VEYY G TSLMQWYQ QKPGKAP KLLIYAA SNVESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYFCQ QSRKDPSTFGGGT KVEI K |
Sacituzumab | Whole mAb ADC | G1 | Kappa | Approved | Active | QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS | DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK | na | na | null | null | null | 2,016 | 2017 | TACSTD2 | IBC Pharmaceuticals;Immunomedics;University of Wisconsin Comprehensive Cancer Center;Yale University | Breast cancer | Prostate cancer;Solid tumours;Urogenital cancer;Endometrial cancer;Glioblastoma | na | na | null | QV QLQQ SGS E LKKPGA SVKVSCK ASGY TFTN YG MNWVK QAPGQGL KWMGWIN TYTGEPT Y TDDFKG RFAFSL DTSVS TAYLQISS LKADDT AVYFCA RGGFGSS YWYFDV WGQG SLVTVS S | DI QLT QSPSS LSA SVGD RVSITCK ASQD VSIAVAWYQ QKPGKAP KLLIYSASYRY TGVPDRFSGSGSGTD FTLTIS SLQPED FAVYYC QQHYITP LTF GAGT KVEI K |
Samalizumab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | QVQLQQSGSELKKPGASVKISCKASGYSFTDYIILWVRQNPGKGLEWIGHIDPYYGSSNYNLKFKGRVTITADQSTTTAYMELSSLRSEDTAVYYCGRSKRDYFDYWGQGTTLTVSS | DIQMTQSPSSLSASIGDRVTITCKASQDINSYLSWFQQKPGKAPKLLIYRANRLVDGVPSRFSGSGSGTDYTLTISSLQPEDFAVYYCLQYDEFPYTFGGGTKLEIK | na | na | null | null | null | 2,010 | 2011 | CD200 | Alexion Pharmaceuticals;The Leukemia & Lymphoma Society | na | na | Acute myeloid leukaemia;Chronic lymphocytic leukaemia;Multiple myeloma;Solid tumours | na | null | QV QLQQ SGS E LKKPGA SVKISCK ASGYSFT DYIILWVR QNPGKG LEWIGHI DPYYGSSNY NLKFK G RVTITA DQSTT TAYMELS SLRSEDT AVYYC GRSKRDY F DYWGQG TTLTVS S | DIQ MT QSPSS LSA SIGD RVTITCK ASQD INSYLSWFQ QKPGKAP KLLIYRA N RLV DGVPS R FSGSGSGTD YTLTISS LQPED FAVYYCLQ YDEFPY T FGGG TKLEI K |
Samrotamab | Whole mAb ADC | G1 | Kappa | Phase-III | Active | EVQLVQSGAEVKKPGASVKVSCKASGYKFSSYWIEWVKQAPGQGLEWIGEILPGSDTTNYNEKFKDRATFTSDTSINTAYMELSRLRSDDTAVYYCARDRGNYRAWFGYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDISNYLNWYQQKPGGAVKFLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGEALPWTFGGGTKVEIK | na | na | null | null | null | 2,017 | 2018 | LRRC15 | AbbVie | na | na | Solid tumours | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY KFSSYWIEWVK QAPGQG LEWIGEI LPGSDTTNYNEKFKDR ATF TSDTS INTAYMELSR LRSDDT AVYYCA RDRGN YRAWFGY WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLNWYQ QKPGGA VKFLIYYT SRLHSGVPS RF SGSGSGTD YTLTIS SLQ PEDFATY FC QQGEALPW T FGGG TKVEI K |
Sarilumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK | na | na | null | null | null | 2,011 | 2012 | IL6R | Asahi Kasei Pharma Corp;Regeneron Pharmaceuticals;Sanofi | Rheumatoid arthritis | Juvenile rheumatoid arthritis | Ankylosing spondylitis;COVID-19;Giant cell arteritis;Polymyalgia rheumatica;Uveitis | VelocImmune Mouse | null | E VQLVES GGG LV QPGR SLRLSC AASRFTFDDY AMHWVR QAPGKGL EWVSGIS WNSGR IGY ADSVKG RFTIS RDNAENS LFLQM NGLRAEDT ALYYC AKGRDS FDIW GQG TMVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYG ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFASYYCQ QANSFPY T FGQGT KLEI K |
Sasanlimab | Whole mAb | G4 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWINWVRQAPGQGLEWMGNIYPGSSLTNYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLSTGTFAYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLWDSGNQKNFLTWYQQKPGQPPKLLIYWTSYRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYFYPHTFGGGTKVEIK | na | na | 6xkr:HL | null | null | 2,019 | 2020 | PDCD1 | Pfizer | na | Bladder cancer;Non-small cell lung cancer;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWINWVR QAPGQG LEWMGNI YPGSSLTNYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCAR LSTGT FAYW GQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSSQSLWDSGNQKN FLTWYQ QKPGQPP KLLIYWTS YRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDY F YPHTFGGG TKVEI K |
Satralizumab | Whole mAb | G2 | Kappa | Approved | NFD | QVQLQESGPGLVKPSETLSLTCAVSGHSISHDHAWSWVRQPPGEGLEWIGFISYSGITNYNPSLQGRVTISRDNSKNTLYLQMNSLRAEDTAVYYCARSLARTTAMDYWGEGTLVTVSS | DIQMTQSPSSLSASVGDSVTITCQASTDISSHLNWYQQKPGKAPELLIYYGSHLLSGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCGQGNRLPYTFGQGTKVEIE | na | na | null | null | null | 2,015 | 2017 | IL6R | Chugai Pharmaceutical;Roche | Neuromyelitis optica | na | Rheumatoid arthritis | na | Satralizumab is the new name for Sapelizumab (PL116) | QV QLQE SGPGL V KPSE TLSLTCAV SGHS I SHDH AWSWVR QPPGEGL EWIGFISY SGITNYNPSLQ GRVTISR DNSKN TLYLQMN SLRAEDT AVYYCA RSLARTTAMDYWGEG TLVTVS S | DI QMT QSPSS LSAS VGD SVTITCQA STDISSHLN WYQ QKPGKAP ELLIYY GSHL L SGVPSRFSGSGSGTD FTFTISS LEAEDA ATYYC GQGNRLP YT FGQGT KVEI E |
Satumomab | Whole mAb Radiolabelled | G1 | Kappa | Approved | NFD | QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSS | DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTRLEIK | na | na | null | 1bbj:HL:BA | null | 1,999 | 2000 | TAG72 | Cytogen Corporation | Radionuclide imaging enhancers | na | na | na | null | QV QLQ QSDA ELV KPGA SVKISCK ASGY TF T DHAIHWAK QKPEQGL EWIGYI SPGNDDIKYNEKFKG KATLTA DKSSST AYMQL NSLTSEDS AVYFCKR S Y YGHWGQG TTLTVS S | DIQ MT QSPA SLSVS VGE TVTITCR ASEN IYSNLAWYQQ KQGKSP QLLVYAAT NLADGVPS R FSGSGSGT QYSLKI NSLQSEDFGS YYCQHF WGTPY T FGGG TRLEI K |
Secukinumab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK | na | na | 6wio:AB/6wir:AB | null | null | 2,009 | 2010 | IL17A | Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon | Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis | Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries | Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis | Abgenix XenoMouse | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS N YWMNWVR QAPGKG LEWVAAI NQDGS EKYYVGSVKGRFTISR DNAKN SLYLQMNSLRV EDT AVYYCVR DYYDILTD YYIHYWYFD LWGRG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP EDF AVYYC Q QYGSSPCTFGQGT RLEI K |
Selicrelumab | Whole mAb | G2 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPDSGGTNYAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARDQPLGYCTNGVCSYFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAPNLLIYTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANIFPLTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | CD40 | Abramson Cancer Center of the University of Pennsylvania;Roche | na | na | Pancreatic cancer;Solid tumours;Non-Hodgkin's Lymphoma | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTGYYMHWVR QAPGQG LEWMGWI NPDSGGTNY AQKF QG RVTMT RDTS ISTAYMEL NRLRSDDT AVYYCA RDQPLG Y CTNGV CSYFD YWGQG TLVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG IY SWLAWY QQKPGKAPN LLIYT ASTLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ ANIF PLTF GGG TKVEI K |
Semorinemab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGLIFRSYGMSWVRQAPGKGLEWVATINSGGTYTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCANSYSGAMDYWGQGTLVTVSS | DDVLTQTPLSLPVTPGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLVPWTFGQGTKVEIK | na | na | null | null | null | 2,018 | 2019 | MAPT | AC Immune;Genentech | na | Alzheimer's disease | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASG LIFRSY G MSWVRQ APGKG LEWVATI NSGG TYTY YPDSVK GRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA NSYSGAMDYWGQG TLVTVS S | DDVLTQTPLSLPVTPGQPA SISC RSSQ SIVH SNGN TYLEWYL QKPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCF QGS LV PW T FGQGT KVEI K |
Semzuvolimab | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGPELKKPGASVKVSCKASGYTFTDYVIHWVKQATGQGLEWIGEIYPGSGSAYSNAKFKDRVTMTADKSSNTAYMELSSLTSDDTAVYFCARRGNGTGFAYWGQGTLVTVSS | DIVLTQSPASLAVSLGQRATITCKAGQSVDYDGDSYMNWYQQKPGQPPKLLIYVASNLESGIPARFSGSGSGTDFTLNIHPVEENDAATYYCQQSYKDPLTFGQGTKLEIK | na | na | null | null | null | 2,022 | na | CD4 | TBC | TBC | TBC | TBC | TBC | null | Q VQLVQ SGPELKKPGA SVKVSCK ASGY TFTDYVIHWVKQ ATGQGL EWIGEI YPGSGSAYSNAKFKD RVTMTA DKSSN TAYMELS SLTSDDT AVYFCAR RGNGT GFAYW GQG TLVTV SS | D IVLT QSPA SLAVS LGQ RATITC KAGQ SVD YDGDS YMNWYQ QKPGQPP KLLIYVA SNLESGIP ARFS GSGSGTD FTLNIHP VEENDA ATYYCQQ SYKDPLTFGQGT KLEI K |
Serclutamab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLQESGPGLVKPSQTLSLTCTVSGYSISRDFAWNWIRQPPGKGLEWMGYISYNGNTRYQPSLKSRITISRDTSKNQFFLKLNSVTAADTATYYCVTASRGFPYWGQGTLVTVSS | DIQMTQSPSSMSVSVGDRVTITCHSSQDINSNIGWLQQKPGKSFKGLIYHGTNLDDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCVQYAQFPWTFGGGTKLEIK | na | na | null | null | null | 2,016 | 2017 | EGFR | AbbVie | na | na | Solid tumours | na | Losatuxizumab and Serclutamab have identical variable domains | E VQLQE SGPGLVKPSQ TLSLTCTV SG YSI SRD FAWNWIR QPPGKGL EWMGYISY NGNTRYQPSLK SRITISR DTSKN QFFLKLN S V TAADTA TYYCVTA SRGFPYWGQ GTLVTVS S | DIQ MT QSPSS MSVS VGD RVTITCH SSQDINSN IGWLQ QKPGKS FKGLIYH GTNLDDGVPS RF SGSGSGTD YTLTISS LQPEDF ATYYCVQYA QFPWTFGGGT KLEI K |
Seribantumab | Whole mAb | G2 | Lambda | Phase-II | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS | QSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL | na | na | null | null | null | 2,012 | 2013 | ERBB3 | Merrimack Pharmaceuticals;Sanofi | na | na | Breast cancer;Gynaecological cancer;Non-small cell lung cancer;Ovarian cancer;Solid tumours | Dyax Human Phage Display | null | E VQLLES GGG LV QPGG SLRLSCA ASGF TFSHYVMAWVR QAPGKG LEWVSSIS SSGG WTLYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC TRGL KMATIFD YWGQG TLVTVS S | QSALTQPA SV SGSPGQ SITISCT GTSSDVG SYNVVSWYQ QHPGKAP KLIIYEVS QRPSGVSNRFSGSKSGN TASLTIS GLQTEDEAD YYCCS YAGS SIFVIF GGGT KVTV L |
Serplulimab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYGMSWIRQAPGKGLEWVSTISGGGSNIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCVSYYYGIDFWGQGTSVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQDVTTAVAWYQQKPGKAPKLLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHYTIPWTFGGGTKLEIK | na | na | 7e9b:HL | null | null | 2,019 | 2020 | PDCD1 | Henlix Biotech;Shanghai Henlius Biotech | Solid tumours | Non-small cell lung cancer;Oesophageal cancer;Small cell lung cancer;Hepatitis B;Gastric cancer;Cervical cancer;Hepatitis B;Liver cancer | na | na | null | Q VQLVES GGG LV KPGG SLRLSC AASGF TFS NYG MSWIR QAPGKGL EWVSTI SGGGSN IYYA DSVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCVSYYY G IDF WGQG TSVTVS S | DIQ MT QSPSS LSA SVGD RVTITCK ASQDV TTAVAWYQ QKPGKAP KLLIYWA STRHTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQHY T IP WT FGGGT KLEI K |
Setoxaximab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | EVQLQQPGPELEKPGASVKLSCKASGYSFTDYNMNWVKQNNGESLEWIGKIDPYYGGPSYNQKFKDKATLTVDKSSSTAYMQLKSLTSEDSAVYYCTRGGNRDWYFDVWGAGTTLTVSA | DIVLSQSPSSLVVSVGEKVTMSCKSSQSLLYSRNQKNYLAWYQQKPGQSPKVLIYWASTRESGVPDRLTGSGSGTDFTLTISSVKAEDLAVYYCQQYYSYPLTFGAGTKLELK | na | na | null | null | null | 2,012 | 2013 | Shiga Toxin Type 2 | Sunol Molecular Corporation;Uniformed Services University of the Health Sciences;BELLUS Health;Taro Pharmaceuticals Inc | na | na | Haemolytic uraemic syndrome;Shiga-toxigenic Escherichia coli infections | na | null | EV QL QQPGPELEKPGA SVKLSCK ASGYS F TDYNM NWVK QNNGE SLEWIGKI DPYYGGPSYNQKFKDK ATLTVD KSSST AYMQLKS LTSEDS AVYYCT RGGNRD WYFDVW GAGT TLTVS A | D IVLS QSPS SLVVS VGE KVTMSC KSSQ SLLYS RNQKN YLAWYQ QKPGQSP KVLIYWAS TRESGVPD RL TGSGSGTD FTLTISS VK AEDL AVYYC QQYYSYP LTF GAGT KLEL K |
Setrusumab | Whole mAb | G2 | Lambda | Phase-II/III | Active | QVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS | DIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL | na | na | null | null | null | 2,017 | 2018 | SOST | MorphoSys;Novartis;Mereo BioPharma | na | Osteogenesis imperfecta | Hypophosphatasia;Postmenopausal osteoporosis | MorphoSys HuCAL Phage Display | null | Q VQLVES GGG LV QPGG SLRLSC AASGF TFRSHWLSWVR QAPGKGL EWVSNIN YDGS STYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARDT YLHFDY WGQG TLVTVS S | DI ALT QPA SV SGSPGQ SITISCT GTSSDVGDIND VSWYQ QHPGKAP KLMIYD VNNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEA D YYC QSY AG SYLSEVF GGGT KLTV L |
Sibeprenlimab | Whole mAb | G2 | Kappa | Phase-III | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYTIHWVRQATGQGLEWMGWIYPLRGSINYAQKFQGRVTMTADKSISTVYMELSSLRSEDTAVYFCARHGAYYSNAFDYWGQGTLVTVSS | EIVMTQSPATLSVSPGERATLSCRASESVDNDGIRFLHWYQQKPGQAPRLLIYRASTRATGIPARFSGSGSRTEFTLTISSLQSEDFAVYYCQQSNKDPYTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | TNFSF13 | Visterra | na | IgA Nephropathy | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TF TD YTIHWVRQ ATGQGL EWMGWIYP LRGS INYA Q KFQG RVTMT ADKS ISTVYMELS SLRSEDT AVYFCA RHGA YY SNAFDYWGQG TLVTV SS | E IVMT QSPA TLSV SPGER ATLSCRAS ESVDNDG IRFLHWYQ QKPGQAP RLLIYRA STRATGIP ARF SGSGSR TEFTLTISS LQSED FAVYYCQ QSNKDPY T FGGG TKVEI K |
Sifalimumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYSISWVRQAPGQGLEWMGWISVYNGNTNYAQKFQGRVTMTTDTSTSTAYLELRSLRSDDTAVYYCARDPIAAGYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVSSTYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK | na | na | 4ypg:HL:BA | null | null | 2,009 | 2010 | IFNA1 | Medarex;MedImmune | na | na | Myositis;Psoriasis;Systemic lupus erythematosus | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYSISWVR QAPGQGL EWMGWISVY NGNTNY AQKF QG RVTMTT DTSTS TAYLELRSL RSDDT AVYYCA RDPIAAG Y WGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS S TYLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEP ED FAVYYC Q QYGSSPRTFGQGT KVEI K |
Siltuximab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSS | QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIK | na | na | null | null | null | 2,008 | 2009 | IL6 | Centocor Inc;Janssen Biotech;Memorial Sloan-Kettering Cancer Center | Giant lymph node hyperplasia | Multiple myeloma | Paraproteinaemia;Myelodysplastic syndromes;Non-Hodgkin's lymphoma;Prostate cancer;Renal cell carcinoma | na | null | E VQLVE SGG KLL KPGG SLKLSC AASGF TFS SFAMSWF RQSPEKR LEWVAEI SSGGS YTY YPDTV TGRFTISR DNAKN TLYLEMS SLRSEDT AMYYC ARGL WGYYALDY WGQGT SVTVS S | Q IVLIQ SPA IMS ASPGE KVTMTCS ASSS VSYMYWYQ QKPGSSP RLLIYD TSNLASGV PVRFS GSGSGT SYSLTISR MEAEDA ATYYCQQ WSGYPY T FGGGT KLEI K |
Simaravibart | Whole mAb | G1 | Kappa | TBC | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYTISWVRQAPGQGLEWMGRIIPILDRVMYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARRAIDSDTYVEQSHFDYWGQGTLVTVSS | EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPSLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQPLTFGGGTKVEIK | na | na | 7s6j:HL:CD:FG/7s6k:HL:CD:FG/7s6l:HL/7sbu:HL | null | null | 2,022 | na | SARS-CoV-2 Spike RBD | TBC | TBC | COVID-19 | TBC | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYTISWVR QAPGQGL EWMGRI IPILDRVMYAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCARRA IDSDT YVEQSHF D Y WGQG TLVTVS S | E IVMT QSPA TLSL SPGE RATLSCR ASQSV S SYLAWYQ QKPGQAP SLLIYD ASNRATG I P ARF SGSGSGT DFTLTIS SLEPED FAVYYC QQPL T FGGG TKVEI K |
Simlukafusp | Whole mAb Fusion | G1 | Kappa | Phase-I | Discontinued | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAIIGSGASTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKGWFGGFNYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQSVTSSYLAWYQQKPGQAPRLLINVGSRRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQGIMLPPTFGQGTKVEIK | na | na | null | null | null | 2,019 | 2020 | FAP | Roche | na | na | Malignant melanoma;Renal cell carcinoma;Solid tumours | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAII GSGAS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KGWFGG FNY WGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQSVTS SYLAWYQ QKPGQAP RLLINV GSRRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QG IM LPPTFGQGT KVEI K |
Simridarlimab | Bispecific Mixed mAb/VH-VH-CH2-CH3 | G1;G1 | Kappa;na | Phase-I | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSIEHYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGKTGSAAWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTVSFPITFGGGTKVEIK | QVQLQESGGGLVQPGGSLRLSCAASAYTISRNSMGWFRQAPGKGLEGVAAIESDGSTSYSDSVKGRFTISLDNSKNTLYLEMNSLRAEDTAVYYCAAPKVGLGPRTALGHLAFMTLPALNYWGQGTLVTVSS | na | None;None | None;None | None;None | 2,021 | 2022 | CD47;CD274 | Innovent Biologics | na | Solid tumours | na | na | null | Q VQLQE SGPGL V KPSE TLSLTCTV SGGS IEHYYWSWIR QPPGKGL EWIGYIYYS GSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGKTGSAAWGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQ TVSFPITF GGG TKVEI K |
Simtuzumab | Whole mAb | G4 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYAFTYYLIEWVRQAPGQGLEWIGVINPGSGGTNYNEKFKGRATITADKSTSTAYMELSSLRSEDTAVYFCARNWMNFDYWGQGTTVTVSS | DIVMTQTPLSLSVTPGQPASISCRSSKSLLHSNGNTYLYWFLQKPGQSPQFLIYRMSNLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPYTFGGGTKVEIK | na | na | null | null | null | 2,012 | 2013 | LOXL2 | Arresto Biosciences;Gilead Sciences | na | na | Colorectal cancer;Hepatic fibrosis;Idiopathic pulmonary fibrosis;Liver cirrhosis;Myelofibrosis;Non-alcoholic steatohepatitis;Pancreatic cancer;Primary sclerosing cholangitis | na | null | Q VQLVQ SGA EVK KPGA SVKVSC KASGY AFTYYLIEWVR QAPGQG LEWIGVI NPGSGGTNYNEKFKG RATITA DKSTS TAYMELS SLRSEDT AVYFCA RNWMN F DYWGQGT TVTV SS | D IVMT QTP LSLSV TPGQP ASISCR SSK SLLH SNGN TYLYWFLQ KPGQSP QFLIYRM SNLASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQH LEYPY T FGGG TKVEI K |
Sintilimab | Whole mAb | G4 | Kappa | Approved | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIK | na | na | null | null | null | 2,018 | 2019 | PDCD1 | Adimab;Innovent Biologics;Jiangsu Provincial Peoples Hospital;Sun Yat-Sen University | Hodgkin's disease | Gastric cancer;Non-small cell lung cancer;Oesophageal cancer;Liver cancer;Extranodal NK-T-cell lymphoma;Small cell lung cancer;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGLIIPMF DTAGY A Q K FQG RVAITV DESTS TAYMELS SLRSEDT AVYYCARAE HSSTG TFDY WGQG TLVTVS S | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLISA ASSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QANHLP FTF GGGT KVEI K |
Sirexatamab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYTMSWVRQAPGKGLEWVATISGGGFGTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARPGYNNYYFDIWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCHASDSISNSLHWYQQKPGQAPRLLIYYARQSIQGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSESWPLHFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | DKK1 | Leap Therapeutics | na | DKK1 | na | na | (June '22: Corrected VH/VL sequences) | E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYTMSWVR QAPGKG LEWVATIS GGGFG TY YPDSVK GRFTISR DNAKNS LYLQMNS LRAEDT AVYYCA RPGYNN YYFDIW GQG TTVTVS S | E IVLTQ SPA TLSL SPGE RATLSCH ASDSISNS LHWYQ QKPGQAP RLLIYYAR QSIQGIP ARFS GSGSGTD FTLTIS SLEPED FAVYYCQ QSESWP LHF GGG TKVEI K |
Sirtratumab | Whole mAb ADC | G2 | Kappa | Phase-I | Active | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNQYYADSVKGRFTISRDNSKNTLFLQMHSLRAEDTAVYYCARGLTSGRYGMDVWGQGTTVTVSS | DIVMTQSPLSLPVTPGEPASISCRSSQSLLLSHGFNYLDWYLQKPGQSPQLLIYLGSSRASGVPDRFSGSGSGTDFTLKISRVEAEDVGLYYCMQPLQIPWTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | SLITRK6 | Astellas/Agensys;Seattle Genetics | na | Bladder Cancer | na | na | null | Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNQ YYAD SVKG RFTISR DNSKN TLFLQMHSL RAEDT AVYYCA RGLTSGR YGMDVW GQG TTVTVS S | DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLLS HGFN YLDWYL QKPGQSP QLLIYL GSSRASGVPDRFSGSGSGT DFTLKISRVE AEDV GLYYCM QPL Q IPW T FGQGT KVEI K |
Sirukumab | Whole mAb | G1 | Kappa | Preregistration | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSPFAMSWVRQAPGKGLEWVAKISPGGSWTYYSDTVTGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARQLWGYYALDIWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCSASISVSYMYWYQQKPGQAPRLLIYDMSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCMQWSGYPYTFGGGTKVEIK | na | na | null | null | null | 2,011 | 2012 | IL6 | Centocor Inc;GlaxoSmithKline;Janssen Biotech | na | COVID-19 | Rheumatoid arthritis;Atherosclerosis;Giant cell arteritis;Asthma;Lupus nephritis;Major depressive disorder | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TF SPF AMSWVR QAPGKG LEWVAKI SPGGS WTYYS DTV TGRFTISR DNAKN SLYLQMN SLRAEDT AVYYC ARQL WG YYALDI WGQGT TVTVS S | E IVLTQ SPA TLSL SPGE RATLSCSASISVSYMYWYQ QKPGQAP RLLIYD MSNLASGIP ARFS GSGSGT DFTLTISS LEPED FAVYYCMQ WSGYPY TF GGG TKVEI K |
Socazolimab | Whole mAb | G1 | Lambda | Preregistration | Active | EVQLVESGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARAPYYYYYMDVWGQGTTVTVSS | QSALTQPASVSGSLGQSVTISCTGSSSDVGSYNLVSWYQQHPGKAPNLMIYDVSKRSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTGISTVVFGGGTKLTVL | na | na | null | null | null | 2,021 | 2022 | CD274 | Sorrento Therapeutics;China Oncology Focus Ltd;Lee's Pharmaceutical | na | Small cell lung cancer;Oesophageal cancer;Osteosarcoma;Urogenital cancer;Cervical cancer;Malignant melanoma | Cancer | na | null | E VQLVE SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWMGGIIPIF GTANYAQKFQG RVTITA DESTS TAYMELS SLRSEDT AVYYCA RAPY YYYYMDV WGQG TTVTVS S | QSALTQPA SVS GSLGQ SVTISCT GSSSDVGS YNLVSWY QQHPGKAPN LMIYD VSKRSGV S NRFSGSKSGN TASLTIS GLQAEDEAD YYCS SYTG ISTVVF GGGT KLTV L |
Sofituzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLVESGGGLVQPGGSLRLSCAASGYSITNDYAWNWVRQAPGKGLEWVGYISYSGYTTYNPSLKSRFTISRDTSKNTLYLQMNSLRAEDTAVYYCARWTSGLDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASDLIHNWLAWYQQKPGKAPKLLIYGATSLETGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYWTTPFTFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | MUC16 | Genentech | na | na | Fallopian tube cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer | na | null | E VQLVES GGG LV QPGG SLRLSC AASGY SI TNDYA WNWVR QAPGKGL EWVGYISY SGY TTY NPSLK SRFTISR DTSKN TLYLQMN SLRAEDT AVYYCARW TSGLDYWGQG TLVTVS S | DIQ M TQSPSS LSA SVGD RVTITCK ASDLIHNWLAWYQ QKPGKAP KLLIYG ATSLETGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YWTTPF T FGQGT KVEI K |
Solanezumab | Whole mAb | G1 | Kappa | Phase-III | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYSMSWVRQAPGKGLELVAQINSVGNSTYYPDTVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCASGDYWGQGTLVTVSS | DVVMTQSPLSLPVTLGQPASISCRSSQSLIYSDGNAYLHWFLQKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK | na | na | null | 4xxd:ED:BA | null | 2,008 | 2009 | APP | Eli Lilly | na | Alzheimer's disease | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYSMSWVR QAPGKG LELVAQIN SVGNST Y YPDTV KGRFTISR DNAKN TLYLQMNS LRAEDT AVYYC ASGDYWGQ GTLVTVS S | DV VMT QSPLSLP VT LGQP ASISC RSSQ SLIYS DGN AYLHWFL QKPGQSP RLLIYKV SNRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCS QSTHVPW T FGQGT KVEI K |
Solitomab | Bispecific scFv | na;na | Kappa;Kappa | Phase-I | Discontinued | EVQLLEQSGAELVRPGTSVKISCKASGYAFTNYWLGWVKQRPGHGLEWIGDIFPGSGNIHYNEKFKGKATLTADKSSSTAYMQLSSLTFEDSAVYFCARLRNWDEPMDYWGQGTTVTVSS | ELVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPLTFGAGTKLEIK | DVQLVQSGAEVKKPGASVKVSCKASGYTFTRYTMHWVRQAPGQGLEWIGYINPSRGYTNYADSVKGRFTITTDKSTSTAYMELSSLRSEDTATYYCARYYDDHYCLDYWGQGTTVTVSS | DIVLTQSPATLSLSPGERATLSCRASQSVSYMNWYQQKPGKAPKRWIYDTSKVASGVPARFSGSGSGTDYSLTINSLEAEDAATYYCQQWSSNPLTFGGGTKVEIK | None;None | None;None | None;None | 2,011 | 2012 | EPCAM;CD3E | Micromet Inc;Amgen | na | na | Solid tumours | na | null | E VQLLEQ SGA ELV RPGT SVKISCK ASGY AFT N YWLGWVK QRPGHGL EWIG D I FPGSGN IHY NEKFKG KATLTA DKSSS TAYMQLSS L T FEDS AVYFCARL RNWDEPMDYWGQG TTVTVS S | EL VMT QSPS SLTVT AGE KVTMSC KSSQS L LNSGNQK NYLTWYQ QKPGQPP KLLIYWAS TRESGVPDR F TGSGSGTD FTLTISSV QAED LAVYYC QNDYSYP LTF GAGT KLEI K |
Sotigalimab | Whole mAb | G1 | Kappa | Phase-II | Active | QVQLVESGGGVVQPGRSLRLSCAASGFSFSSTYVCWVRQAPGKGLEWIACIYTGDGTNYSASWAKGRFTISKDSSKNTVYLQMNSLRAEDTAVYFCARPDITYGFAINFWGPGTLVTVSS | DIQMTQSPSSLSASVGDRVTIKCQASQSISSRLAWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQCTGYGISWPIGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | CD40 | Apexigen | na | Pancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma | Brain cancer;Glioma;Solid tumours | na | null | Q VQLVES GGG VV QPGR SLRLSCA ASGFS F S STYVCWVRQ APGKG LEWIACIYT GDGTN YSASW AKG RFTISK DSSKN TVYLQMN SLRAED TAVYFCA RPDI TYGFAINFW GPG TLVTVS S | DI QMT QSPSS LSA SVGD RVTIKCQ ASQS I S SRLAWYQ QKPGKPP KLLIYRA STLASGVPS R FSGSGSGTD FTLTISS LQPEDV ATYYCQC TGYG IS WPIGGG TKVEI K |
Sotevtamab | Whole mAb | G2 | Kappa | Phase-II | Active | QVQLVQSGAEVKKPGATVKISCKVSGFNIKDIYMHWVQQAPGKGLEWMGRIDPAYGNTKYDPKFQGRVTITADTSTDTAYMELSSLRSEDTAVYYCARRYDTAMDYWGQGTLVTVSS | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSRTRKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCKQSYNLWTFGQGTKLEQL | na | na | null | null | null | 2,021 | 2022 | CLU | Alethia Biotherapeutics | na | Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGA TVKISCKV SGFN I K DIYMHWVQ QAPGKG LEWMGRI DPAYGNTKYDPKFQG RVTITA DTSTDT AYMELS SLRSEDT AVYYCARR YDTAMDYWGQG TLVTVS S | D IVMT QSPDS LAVS LGER ATINC KSS QSLL NSRT RKNYLAWYQ QKPGQPP KLLIYWA STRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCK QSYN LWTF GQGTK LE QL |
Sotrovimab | Whole mAb | G1 | Kappa | Approved | Active | QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS | EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK | na | na | null | 7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7jwl:DC:GF:HL/7l0n:CD:AB/7nd8:HL/7r6x:AB/7r6w:AB/7tly:AB/7tm0:ED:GF:IH/7tn0:BA:CD | 7sob:GI:HJ:NO/7soc:HL | 2,020 | 2021 | SARS-CoV-2 Spike RBD | GlaxoSmithKline;Vir Biotechnology | COVID-19 | na | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGYPFT SYGISWVRQ APGQGL EWMGWISTY QGNTNY AQKF QG RVTMTT DTSTTT GYMELRRL RSDDT AVYYCAR DYTRGA WF GE SLI GG F DNWGQG TLVTVS S | E IVLTQ SPG TLSL SPGE RATLSCR ASQ TV SST SLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QHDT SLTF GGG TKVEI K |
Spartalizumab | Whole mAb | G4 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLRISCKGSGYTFTTYWMHWVRQATGQGLEWMGNIYPGTGGSNFDEKFKNRVTITADKSTSTAYMELSSLRSEDTAVYYCTRWTTGTGAYWGQGTTVTVSS | EIVLTQSPATLSLSPGERATLSCKSSQSLLDSGNQKNFLTWYQQKPGQAPRLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLEAEDAATYYCQNDYSYPYTFGQGTKVEIK | na | na | null | null | null | 2,017 | 2018 | PDCD1 | Asan Medical Center;Dana-Farber Cancer Institute;Novartis;Novartis Oncology;Palobiofarma;Seoul National University Hospital | na | Malignant melanoma;Breast cancer;Colorectal cancer;Diffuse large B cell lymphoma;Gastric cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Solid tumours;Acute myeloid leukaemia;Cancer;Liver cancer;Lymphoma;Multiple myeloma;Myelodysplastic syndromes;Ovarian cancer;Pancreatic cancer;Renal cancer | Neuroendocrine tumours | na | null | E VQLVQ SGA EVK KPGE SLRISC KGSGY TFTTYWMHWVRQ ATGQG LEWMGNI YPGTGGSNFDEKFKN RVTITA DKSTS TAYMELSS LRSEDT AVYYCTRWT TGTGA YW GQG TTVTVS S | E IVLT QSPA TLSL SPGE RATLSC KSSQS L LDSGNQKN FLTWYQ QKPGQAP RLLIYWAS TRESGVPS RF SGSGSGTD FTFTISS LEAEDA A TYYC QNDYSYPY T FGQGT KVEI K |
Spesolimab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTSSWIHWVKQAPGQGLEWMGEINPGNVRTNYNENFRNKVTMTVDTSISTAYMELSRLRSDDTAVYYCTVVFYGEPYFPYWGQGTLVTVSS | QIVLTQSPGTLSLSPGERATMTCTASSSVSSSYFHWYQQKPGQAPRLWIYRTSRLASGVPDRFSGSGSGTDFTLTISRLEPEDAATYYCHQFHRSPLTFGAGTKLEIK | na | na | 6u6u:HL | null | null | 2,018 | 2019 | IL36RN | Boehringer Ingelheim | na | Ulcerative colitis;Atopic dermatitis;Crohn's disease;Palmoplantar pustulosis;Pustular psoriasis | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY SFTSSWIHWVK QAPGQGL EWMGEI NPGNV RT NYNENFRN KVTMTV DTSI STAYMELSRL RSDDT AVYYCTVVFY GEPYFPYWGQ GTLVTVS S | Q IVLTQ SPG TLSL SPGER ATMTCTA SSSVSSS YFHWYQ QKPGQAP RLWIYRT SRLASGVPDRFSGSGSGT DFTLTISR LEPEDAA TYYCHQ FHRSPL TF GAGT KLEI K |
Stamulumab | Whole mAb | G1 | Lambda | Phase-I/II | Discontinued | EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDENWGFDPWGQGTLVTVSS | SYELTQPPSVSVSPGQTASITCSGHALGDKFVSWYQQKPGQSPVLVIYDDTQRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSFVFGGGTKVTVL | na | na | null | null | null | 2,006 | 2006 | GDF8 | Cambridge Antibody Technology;Wyeth | na | na | Muscular dystrophies;Sarcopenia | na | null | E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGII NPSGGSTSY AQKF QG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RDENWGFDPWGQG TLVTVS S | SYELTQPPS VSV SPGQ TASITC SGHALGD KFVSWYQ QKPGQSP VLVIY DDTQRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQA WDSS FVF GGGT KVTV L |
Suciraslimab | Whole mAb | G1 | Kappa | Phase-III | Active | QVQLQESGGGLVKPGGSLKLSCAASGFAFSIYDMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCARHSGYGSSYGVLFAYWGQGTLVTVSS | DIQLTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSILHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPWTFGGGTKLEIK | na | na | null | null | null | 2,021 | 2022 | CD22 | Lonn Ryonn Pharma; SinoMab Bioscience Ltd | na | Rheumatoid arthritis;Non-Hodgkin's lymphoma;Systemic lupus erythematosus;Sjogren's syndrome | na | na | null | Q VQLQE SGGG LV KPGG SLKLSC AASGF AFSIYD M SWVR QTPEKR LEWVAYIS SGGGT TY YPDTV KGRFTISR DNAKN TLYLQMS SLKSEDT AMYYCAR HSGYGSSY GVLFAYW GQG TLVTVS S | DI QLTQ TTS SLS ASLGD RVTISCR ASQD ISNYLNWYQ QKPDGT VKLLIYYTSIL HSGVPSRFSGSGSGTD YSLTIS NLEQE DFATY FC QQGNTLP WT FGGGT KLEI K |
Sudubrilimab | Whole mAb | G1 | Kappa | Unknown | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSETWLHWVRQAPGKGLEWVAWVSPFGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFLYHPATFGQGTKVEIK | na | na | null | null | 5x8l:GL:FK:SN:HM:JO/5xxy:HL | 2,020 | 2021 | CD274 | Zhejiang Hisun Pharmaceutical | na | TBC | TBC | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS E TWLHWVR QAPGKG LEWVAWV SPFGGS TYYAD SVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCAR RHWPGGFD Y WGQG TLVTV SS | DIQ MT QSPSS LSA SVGD RVTITCR ASQD VSTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFATY YCQQFLY HPATFGQGT KVEI K |
Sugemalimab | Whole mAb | G4 | Lambda | Approved | Active | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGISGSGGFTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPPRGYNYGPFDYWGQGTLVTVSS | SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL | na | na | null | null | null | 2,019 | 2020 | PDL1 | Cstone Pharmaceuticals | Non-small cell lung cancer | Cancers;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer | na | na | null | E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKG LEWVS GISGSGG FTYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPPRGYNYGPFDYWGQG TLVTVS S | SY VL TQPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE R FSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L |
Suptavumab | Whole mAb | G1 | Kappa | Phase-III | Discontinued | EVQLVESGGDLVQPGRSLRLSCVASGFTFDDYAMHWVRQAPGKGLEWVSGVSWSGSTVGYADSVKGRFTVSRDNAQKSLYLQMNSLRAEDTALYYCVKDAYKFNYYYYGLDVWGQGTTVTVSS | EIVMTQSPATLSVSPGERATLSCRASQTILSNLAWYLQKPGQAPRLLIYGASTRATGLPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPLTFGGGTKVEIK | na | na | null | null | null | 2,016 | 2017 | RSV gpF | Regeneron Pharmaceuticals | na | na | Respiratory syncytial virus infections | VelocImmune Mouse;VelociGene | null | E VQLVE SGGD LV QPGR SLRLSCVA SGFTFDDY AMHWVR QAPGKG LEWVSGVS WSGS TVGY ADSVKG RFTVS RDNAQK SLYLQMN SLRAEDT ALYYCVK DAYKFN YYYYGLDV WGQG TTVTVS S | E IVMT QSPA TLSV SPGE RATLSCR AS QTILSNLAWYL QKPGQAP RLLIYG ASTRATGLP ARF SGSGSGT EFTLTISS LQSED FAVYYCQ QYNNWP LTF GGG TKVEI K |
Surzebiclimab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYAMSWVRQAPGKGLEWVAAISSGGSLYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARGREADGGYFDYWGQGTLVTVSS | EIVLTQSPATLSVSPGERATLSCRASESVEYYGTSLMQWYQQKPGQAPRLLIYAASNVESGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQSLKVPLTFGGGTKVEIK | na | na | null | null | null | 2,020 | 2021 | HAVCR2 | BeiGene | na | Solid tumours | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFSRYAMSWVR QAPGKGL EWVAAIS SGGS LY YPDSVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCA RGREADGG YFDY WGQG TLVTVS S | E IVLT QSPA TLSV SPGE RATLSCR ASES VEYY GT S LMQWY QQKPGQAP RLLIYAA SNVESGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQ QSLKVP LTF GGG TKVEI K |
Sutimlimab | Whole mAb | G4 | Kappa | Approved | NFD | EVQLVESGGGLVKPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVATISSGGSHTYYLDSVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARLFTGYAMDYWGQGTLVTVSS | QIVLTQSPATLSLSPGERATMSCTASSSVSSSYLHWYQQKPGKAPKLWIYSTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYYRLPPITFGQGTKLEIK | na | na | null | null | null | 2,017 | 2018 | C1S | Bioverativ;True North Therapeutics | Autoimmune haemolytic anaemia | na | Idiopathic thrombocytopenic purpura;Bullous pemphigoid;Renal transplant rejection | na | null | E VQLVES GGG LV KPGG SLRLSC AASGF TFS NY AMSWVR QAPGKG LEWVATIS SGGS HTYYLD SVKG RFTISR DNSKN TLYLQMN SLRAED TALYYCARLF TGY AM DYWGQG TLVTV SS | Q IVLTQ SPA TLSL SPGER ATMSCTA SSSVSSS YLHWYQ QKPGKAP KLWIYS TSNLASGVPS R FSGSGSGTD YTLTISS LQP EDFAT YYCHQYY RLPPI T FGQGT KLEI K |
Suvizumab | Whole mAb | G1 | Kappa | Phase-I | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNSWIGWFRQAPGQGLEWIGDIYPGGGYTNYNEIFKGKATMTADTSTNTAYMELSSLRSEDTAVYYCSRGIPGYAMDYWGQGTLVTVSS | DIQMTQRPDSLSASVGDRVTMSCKSSQSLLNSGDQKNYLTWYQQKPGQPPKLLIYWASTGESGVPDRFSGSGSGTDFTFTISSLQPEDIATYYCQNDYSYPWTFGQGTKVEIK | na | na | 3ntc:HL | null | null | 2,009 | 2010 | HIV-1 gp120 | Kaketsuken;Kumamoto University;University of Missouri-Columbia | na | na | HIV-1 infections | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFT NS WIGWFR QAPGQGL EWIGDI YPGGGYTNYN EIF KG KATMTA DTSTN TAYMELS SLRSEDT AVYYC SRGIPGY AMD YWGQG TLVTV SS | DIQ M TQRPDS LSAS VGD RVTMSC KSSQS L LNSGDQKN YLTWYQ QKPGQPP KLLIYWA STGESGVPDRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QNDYSYPW T FGQGT KVEI K |
Suvratoxumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSHDMHWVRQATGKGLEWVSGIGTAGDTYYPDSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDRYSPTGHYYGMDVWGQGTTVTVSS | DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCKQYADYWTFGQGTKVEIK | na | na | 4u6v:HL:KM | null | null | 2,016 | 2017 | Toxin A | Biosynexus;GlaxoSmithKline;Regeneron Pharmaceuticals;MedImmune | na | Nosocomial pneumonia | na | na | null | E VQLVES GGG LV QPGG SLRLSC AASGF TFS SHDM HWVRQ ATGKGL EWVS GIGTAGDT Y YPDSVK GRFTIS RENAKNS LYLQMNS LRAGD TAVYYCA RDRYSPTGH YYGMDV WGQG TTVTVS S | DIQ M TQSPS TLSAS VGD RVTITCR ASQS ISSWLAWYQ QKPGKAP KLLIYKA SSLESGVPS R FSGSGSGT EFTLTIS SLQPDD FA TYYC K QYAD YWTF GQGT KVEI K |
Tabalumab | Whole mAb | G4 | Kappa | Phase-III | Discontinued | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGYYDILTGYYYYFDYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDSTLTISSLEPEDFAVYYCQQRSNWPRTFGQGTKVEIK | na | na | null | null | null | 2,011 | 2012 | TNFSF13B | Eli Lilly | na | na | Multiple myeloma;Multiple sclerosis;Renal failure;Rheumatoid arthritis;Systemic lupus erythematosus | na | null | QV QLQQW GAGLLKPSE TLSLTCAVY GGSFS GYYWSWIR QPPGKGL EWIGEIN HSGSTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RGY YD ILTG YYYYFDY WGQG TLVTVS S | E IVLT QSPA TLSL SPGE RATLSCR ASQS VSRYLAWYQ QKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTDS TLTIS SLEPED FAVYYCQ QRSNWPRTFGQGT KVEI K |
Tabituximab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | EVQLQQSGAELVKPGASVKLSCTASGFNINDTYMHWVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQLSSLTSEDTAVYYCARGARGSRFAYWGQGTLVTVSA | DIQMTQSPASLSVSVGETVTITCRASENIYSNLAWYQQKQGKSPQLLVYVATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGSYYCQHFWGTPYTFGGGTKLEIK | na | na | null | null | null | 2,018 | 2019 | FZD10 | OncoTherapy Science;Centre Leon Berard | na | na | Synovial sarcoma | na | null | E VQLQQ SGA ELV KPGA SVKLSCT ASGFNINDT YMHWVK QRPEQGL EWIGRI DPANGNTKYDPKFQG KATITA DTSSN TAYLQLS SLTSEDT AVYYCA RGARGS RFAYW GQG TLVTVS A | DIQ MT QSPA SLSVS VGE TVTITCR ASEN IYSNLAWYQQ KQGKSPQ LLVYVAT NLADGVPS RF SGSGSGT QYSLKI NSLQSEDFGS YYCQHF WGTPY T FGGGT KLEI K |
Tacatuzumab | Whole mAb ADC | G1 | Kappa | Phase-I | Discontinued | QVQLQQSGAEVKKPGSSVKVSCKASGYAFTSYVIHWVRQAPGQGLYWIGYIHPYNGGTKYNEKFKGKATITADESTNTAYMELSSLRSEDTAFYFCARSGGGDPFAYWGQGSLVTVSS | DIQLTQSPSSLSASVGDRVTITCKASQDINKYIGWYQQKPGKAPKLLMHYTSALLPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDDLWTFGGGTKLQIK | na | na | null | null | null | 2,005 | 2006 | Alpha Ferroprotein | Immunomedics | na | na | Liver cancer | na | null | Q VQLQQ SGA EVK KPGS SVKVSCK ASGY AFTSYVIHWVR QAPGQG LYWIGYIH PYNGGTKYNEKFKG KATITA DESTN TAYMELS SLRSEDT AFYFCAR SGGGDPF AYW GQG SLVTV SS | DI QLT QSPSS LSA SVGD RVTITCK ASQD INKY IGWYQ QKPGKAP KLLMHYT SALLPGIPSRFSGSGSGRD YTFTIS SLQPEDI ATYYCLQ YDD LWTF GGGT KLQI K |
Tadocizumab | Fab | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGSSVKVSCKASGYAFTNYLIEWVRQAPGQGLEWIGVIYPGSGGTNYNEKFKGRVTLTVDESTNTAYMELSSLRSEDTAVYFCARRDGNYGWFAYWGQGTLVTVSS | DIQMTQTPSTLSASVGDRVTISCRASQDINNYLNWYQQKPGKAPKLLIYYTSTLHSGVPSRFSGSGSGTDYTLTISSLQPDDFATYFCQQGNTLPWTFGQGTKVEVK | na | na | null | null | null | 2,005 | 2006 | ITGA2B_ITGB3 | PDL BioPharma;Yamanouchi | na | na | Coronary artery restenosis;Stroke;Thrombosis | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGY AFTNY LIEW V R QAPGQGL EWIGVIY PGSGGTNYNEKFKG RVTLTVD ESTN TAYMELSS LRSEDT AVYFCAR RDGN YGWFAYW GQG TLVTVS S | DIQMTQTPS TLSAS VGD RVTISCR ASQD INNYLNWYQ QKPGKAP KLLIYYT STLHSGVPSRFSGSGSGTD YTLTIS SLQPDD FA TYFC QQGNTLPW T FGQGT KVEV K |
Tafasitamab | Whole mAb | G1 | Kappa | Approved | Active | EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYWGQGTLVTVSS | DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK | na | na | null | null | null | 2,018 | 2019 | CD19 | MorphoSys;The Ohio State University Comprehensive Cancer Center;Xencor | Diffuse large B cell lymphoma | Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Precursor B-cell lymphoblastic leukaemia-lymphoma;Follicular lymphoma;Marginal zone B-cell lymphoma | na | MorphoSys HuCAL Phage Display;XmAb Engineering Technology | null | E VQLVES GGG LV KPGG SLKLSC AASGY TFTSYVMHWVR QAPGKGL EWIGYI NPYNDGTKYNE KF Q GRVTIS SDKS ISTAYMELS SLRSEDT AMYYC ARGT YYY G TRVFD YWGQG TLVTVS S | D IVMT QSPA TLSL SPGE RATLSCR SSKSL Q NVNGN TYLYWFQ QKPGQSP QLLIYRM SNLNSGVPDRFSGSGSGT EFTLTIS SLEPED FAVYYCM QHLEYP ITF GAGT KLEI K |
Tafolecimab | Whole mAb | G2 | Kappa | Preregistration | Active | QLQLQESGPGLVKPSETLSLTCTVSGGSISSASYYWSWIRQPPGKGLEWIGSINYRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARENSGVVPAAGPNWFGPWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRRNWFTFGGGTKVEIK | na | na | null | null | null | 2,019 | 2020 | PCSK9 | Innovent Biologics | na | Hypercholesterolaemia | na | na | null | QL QLQE SGPGL V KPSE TLSLTCTV SGGSISSA SYYWSWIR QPPGKGL EWIGSINY RGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCAR ENSGVVPAAGPNWFGPWGQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRRN WFTF GGG TKVEI K |
Tagitanlimab | Whole mAb | G1 | Kappa | Preregistration | Active | QVQLQESGPGLVKPSETLSITCTVSGFSLSNYDISWIRQPPGKGLEWLGVIWTGGATNYNPALKSRLTISRDNSKNQVSLKMSSVTAADTAVYYCVRDSNYRYDEPFTYWGQGTLVTVSS | EIVLTQSPDTLSVTPKEKVTLTCRASQSIGTNIHWFQQKPGQSPKLLIKYASESISGVPSRFSGSGSGTDFTLTINSVEAEDAATYYCQQSNSWPYTFGQGTKLEIK | na | na | null | null | null | 2,021 | 2022 | CD274 | Sichuan Kelun-Biotech Biopharmaceutical | na | Hodgkin Lymphoma;Nasopharyngeal Carcinoma | na | na | (June '22: Corrected FWL4 sequence) | Q VQLQE SGPGL V KPSE TLSITCTV SGF S LSN YDISWIR QPPGKGL EWLGVIWT GGATNYNPALK SRLTISR DNSKN QVSLKMSS VTAADT AVYYCVR DSNYRYDEPF TYW GQG TLVTVS S | E IVLTQ SPD TLSV TPKE KVTLTCR ASQSIGT NIHWFQ QKPGQSP KLLIKYA SESISGVPS R FSGSGSGT DFTLTINSV EAEDA ATYYCQ QSNSWP YT FGQGT KLEI K |
Talacotuzumab | Whole mAb | G1 | Kappa | Phase-II | Active | EVQLVQSGAEVKKPGESLKISCKGSGYSFTDYYMKWARQMPGKGLEWMGDIIPSNGATFYNQKFKGQVTISADKSISTTYLQWSSLKASDTAMYYCARSHLLRASWFAYWGQGTMVTVSS | DIVMTQSPDSLAVSLGERATINCESSQSLLNSGNQKNYLTWYQQKPGQPPKPLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNDYSYPYTFGQGTKLEIK | na | na | 4jzj:HL:AB | null | null | 2,017 | 2018 | IL3RA | CSL;Janssen Biotech | na | Myelodysplastic syndromes | Acute myeloid leukaemia;Systemic lupus erythematosus | na | null | E VQLVQ SGA EVK KPGE SLKISC KGSGYS FTDYYMKWARQ MPGKGL EWM GD II PSNGA TFY NQKFKG QVTIS ADKS ISTTYLQWS SLKASDT AMYYC ARSHL LRASWFAYW GQG TMVTV SS | D IVMT QSPDS LAVS LGE RATINC ESSQ SL LNSGNQKN YLTWYQ QKPGQPPKP LIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC QNDYSYPY T FGQGT KLEI K |
Talizumab | Whole mAb | G1 | Kappa | Phase-II | Discontinued | QVQLVQSGAEVKKPGASVKVSCKASGYTFSMYWLEWVRQAPGHGLEWVGEISPGTFTTNYNEKFKARATFTADTSTNTAYMELSSLRSEDTAVYYCARFSHFSGSNYDYFDYWGQGTLVTVSS | DILLTQSPGTLSLSPGERATLSCRASQSIGTNIHWYQQKPGQAPRLLIKYASESISGIPSRFSGSGSGTDFTLTISRLEPEDFAMYYCQQSDSWPTTFGQGTKVEIK | na | na | null | null | null | 2,002 | 2004 | IgE | Tanox | na | na | Peanut hypersensitivity | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFSMYWLEWVR QAPGHG LEWVGEI SPGT FTT NYNEK FKARATFTA DTSTN TAYMELSS LRSEDT AVYYCARFS HFSGSNYD YFDY WGQG TLVTVS S | D ILLTQ SPG TLSL SPGE RATLSCR ASQSIGT NIHWYQ QKPGQAP RLLIKYA SESISGIPSRFSGSGSGTD FTLTISR LEPED FAMYYCQ QSDSWPTTFGQG TKVEI K |
Talquetamab | Bispecific mAb | G4;G4 | Kappa;Lambda | Phase-II | Active | QVQLVQSGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQGLEWMGLINPYNSDTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVALRVALDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCKASQNVATHVGWYQQKPGKAPKRLIYSASYRYSGVPSRFSGSGSGTEFTLTISNLQPEDFATYYCQQYNRYPYTFGQGTKLEIK | EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARHGNFGNSYVSWFAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNLWVFGGGTKLTVL | None;None | None;None | None;None | 2,019 | 2020 | GPRC5D;CD3E | Genmab;Janssen Research & Development | na | Multiple myeloma | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY SFTGYTMNWVR QAPGQG LEWMGLI NPYNSDTN YAQ K LQG RVTMTT DTSTS TAYMELRS LRSDDT AVYY CARVALRVALDY WGQG TLVTV SS | DI QMT QSPSS LSA SVGD RVTITCK ASQN VATHVGWYQ QKPGKAPK RLIYSASYRY SGVPSRFSGSGSGT EFTLTIS NLQ PEDFA TYYCQ QYNRYPY T FGQGT KLEI K |
Tamgiblimab | Whole mAb | G4 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGASVKVSCKASGYTFTEYYMHWVRQAPGQGLEWMGIISPSAGSTKYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDHDIRLAGRLADYWGQGTLVTVSS | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAVILPITFGGGTKVEIK | na | na | null | null | null | 2,021 | 2022 | TIGIT | Innovent Biologics | na | Cancer | na | na | null | Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTEYYMHWVR QAPGQG LEWMGII SPSAGSTK YAQ K FQG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RDHD IRLAGRL AD YWGQG TLVTV SS | DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLISA ASSLQSGVPS RF SGSGSGTD FTLTIS SLQP EDFA TYYC QQ AVILPITF GGG TKVEI K |
Tamrintamab | Whole mAb ADC | G1 | Kappa | Phase-I | Active | QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYWIEWVRQAPGQGLEWMGEILPGSGNTYYNERFKDRVTITADESTSTAYMELSSLRSEDTAVYYCARRAAAYYSNPEWFAYWGQGTLVTVSS | EIVLTQSPATLSLSPGERATLSCTASSSVNSFYLHWYQQKPGLAPRLLIYSTSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHRSPYTFGQGTKLEIK | na | na | 6vgr:HL:CD | null | null | 2,018 | 2019 | DPEP3 | Stemcentrx | na | Ovarian cancer;Solid tumours | na | na | null | Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYWIEWVR QAPGQG LEWMGEI LPGSGNT YY NERFKD RVTITA DESTS TAYMELS SLRSEDT AVYY CARRAAAYY SNP EW FAYW GQG TLVTVS S | E IVLTQ SPA TLSL SPGE RATLSCTA SSSVN SFYLHWYQ QKPGLAP RLLIYS TSNLASGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCH QYHRSPYTFGQGT KLEI K |
Tamtuvetmab | Canine Whole mAb | G2 | Kappa | Unknown | Active | EVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS | DIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL | na | na | null | null | 1bfo:HG:FE:BA:DC | 2,015 | 2016 | CD52 | Aratana Pharmaceuticals | na | Canine T-cell lymphoma | na | na | null | E VKLLES GGG LV QPGGS MRLSC AGSGF TFTDFYMNWIR QPAGKAPE W LGFIR DKAKGY TTE YNPSVK GRFTISR DNTQN MLYLQMNTL RAEDT ATYYCA REGHTAAPFDYWGQG TLVTVS S | DIKMTQSPS FLS ASVGD RVTLNC KAS Q N IDKYLNWYQQKL GESP KLLIYN TNNLQTGIPSRFSGSGSGTD FTLTIS SLQ PEDVATYFCLQH ISRPRTFGGGT HLTV L |
Tanezumab | Whole mAb | G2 | Kappa | Preregistration | Active | QVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS | DIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK | na | na | 4edw:HL | null | null | 2,008 | 2009 | NGFB | Rinat Neuroscience;Pfizer | na | Back pain;Musculoskeletal pain | Diabetic neuropathies;Postherpetic neuralgia;Cancer pain | na | null | QV QLQE SGPGL V KPSE TLSLTCTV SG FSLIGYDLNWIR QPPGKGL EWIGIIW GDGTTDYNSA VKSRVTIS KDTSKN QFSLKLSS VTAADT AVYYCA RGG YWYATSYYF DYWGQG TLVTVS S | DI QMT QSPSS LSA SVGD RVTITCR ASQSISNNLN WYQ QKPGKAP KLLIYYT SRFHSGVPSRFSGSGSGTD FTFTIS SLQ PEDIA TYYC QQEHTLP YT FGQGT KLEI K |
Tarcocimab | Whole mAb | G1 | Kappa | TBC | Active | EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSS | DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK | na | na | 1cz8:HL:YX | null | 1bj1:HL:KJ/6bft:HL:AB | 2,021 | 2022 | VEGFA | TBC | TBC | TBC | TBC | TBC | Name corrected from tarcolimab in previous version | E VQLVES GGG LV QPGG SLRLSCA ASGYDF THYGMNWVR QAPGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPYYYGTS HWYFDV WGQG TLVTVS S | DI QLT QSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K |
Tarextumab | Whole mAb | G2 | Kappa | Phase-II | Active | EVQLVESGGGLVQPGGSLRLSCAASGFTFSSSGMSWVRQAPGKGLEWVSVIASSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSIFYTTWGQGTLVTVSS | DIVLTQSPATLSLSPGERATLSCRASQSVRSNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYSNFPITFGQGTKVEIK | na | na | null | null | null | 2,013 | 2014 | NOTCH2&3 | OncoMed Pharmaceuticals | na | Pancreatic cancer;Small cell lung cancer | Solid tumours | MorphoSys HuCAL Phage Display;XmAb Engineering Technology | null | E VQLVES GGG LV QPGG SLRLSC AASG FTFS SSGM SWVRQ APGKGL EWVSVIA SSGSNT YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARSIFYT TWGQG TLVTVS S | D IVLTQ SPA TLSL SPGE RATLSCR ASQSVR SN YLAWYQ QKPGQAP RLLIYG ASSRATGVP ARF SGSGSGT DFTLTIS SLEP ED FAVYYCQ QYSNFP ITF GQGT KVEI K |
Tarlatamab | Bispecific scFv | na;na | Kappa;Lambda | Phase-II | Active | QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGYVYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAVTGFYFDYWGQGTLVTVSS | EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK | EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS | QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL | None;None | None;None | None;None | 2,020 | 2021 | DLL3;CD3E | Amgen | na | Small cell lung cancer | na | BiTE Technology | null | QV QLQE SGPGL V KPSE TLSLTCTV SGGS ISSYYWSWIR QPPGKC LEWIGYVYYS GTTNYNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCASIAVTGFYFD YWGQG TLVTV SS | E IVLTQ SPG TLSL SPGE RVTLSCRA SQRVNNN YLAWYQ QRPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QYDRSPL TF GCGT KLEI K |
Tarperprumig | Bispecific Single Domains (VH-VH') | na;na | na;na | TBC | Active | QVQLVESGGGLVKPGGSLRLSCAASGRPVSNYAAAWFRQAPGKEREFVSAINWQKTATYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAAVFRVVAPKTQYDYDYWGQGTLVTVSS | na | EVQLLESGGGLVQPGGSLRLSCAASGRISSIIHMAWFRQAPGKERELVSEISRVGTTVYADSVKGRFTISRDNSKNTLYLQMNSLKPEDTAVYYCNALQYEKHGGADYWGQGTLVTVSS | na | None;None | None;None | None;None | 2,022 | na | CFP;ALB | TBC | TBC | TBC | TBC | TBC | null | Q VQLVES GGG LV KPGG SLRLSC AASGRPVS NYAAAWF R QAPGKER EFVSAIN WQKTA TY ADSVK GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAAVFRVV APKTQYDYD Y WGQG TLVTVS S | null |